Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.61 |
| ▸ | MC4R | P32245 | 3/20 | 0.60 |
| ▸ | MC5R | P33032 | 2/20 | 0.60 |
| ▸ | MC3R | P41968 | 2/20 | 0.60 |
| ▸ | MC1R | Q01726 | 2/20 | 0.60 |
| ▸ | CXCR4 | P61073 | 10/20 | 0.59 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.58 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | CALCA | P06881 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21386022 | 0.95 | C5AR1 (0.65) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL16455572 | 0.92 | MC4R (0.65) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL16455231 | 0.90 | C5AR1 (0.68) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL29164274 | 0.90 | MC4R (0.62) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL29164282 | 0.90 | MC4R (0.62) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL31650786 | 0.90 | MC4R (0.64) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL31187042 | 0.89 | CXCR4 (0.63) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL31378995 | 0.89 | C5AR1 (0.63) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL30717244 | 0.87 | GHSR (0.60) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL29835266 | 0.86 | MC4R (0.61) | IL23RMC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2019-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | F12, RPS4Y1, NPY1R | IL23R 1554/4885MC4R 534/4885MC5R 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.